Post-treatment Surveillance

Following the treatment of skin cancer, structured post-treatment surveillance is essential for the early detection of recurrence, regional metastases, and new primary skin cancers. Evidence-based surveillance protocols are tailored to the type and stage of the original cancer, ensuring that patients receive appropriate follow-up care during the period of highest risk.

Why Post-treatment Surveillance Matters

Patients who have been treated for skin cancer face an elevated risk of developing additional skin cancers in the future. Studies have demonstrated that a history of one skin cancer significantly increases the likelihood of developing another, whether at the original site or elsewhere on the body. For melanoma patients, the risk of a second primary melanoma is substantially higher than the risk in the general population.

Regular surveillance enables the identification of local recurrence, in-transit or regional metastatic disease, and new primary tumours at the earliest possible stage, when treatment is most effective and outcomes are most favourable.

Surveillance Schedules

Surveillance frequency is determined by the type and stage of the skin cancer that was treated. Evidence-based guidelines recommend the following general schedules:

Basal Cell Carcinoma

Patients treated for basal cell carcinoma are typically monitored every 6 to 12 months for a period of 5 years. The majority of recurrences occur within the first 3 years following treatment. After the initial 5-year surveillance period, annual skin examinations are recommended on an ongoing basis, as the risk of developing a new basal cell carcinoma remains elevated.

Squamous Cell Carcinoma

For squamous cell carcinoma, surveillance is more frequent during the initial post-treatment period due to the higher risk of metastasis. Examinations are recommended every 3 to 6 months for the first 2 years, then every 6 to 12 months thereafter. High-risk squamous cell carcinomas, such as those with perineural invasion, poor differentiation, or large size, may require more intensive monitoring.

Melanoma

Melanoma surveillance follows the most intensive protocol due to the potential for late recurrence and metastatic disease. Clinical examinations are performed every 3 to 6 months for the first 3 to 5 years, followed by annual examinations. The exact schedule is determined by the stage of the original melanoma, with higher-stage disease warranting more frequent follow-up.

What Is Monitored

Each surveillance visit involves a thorough assessment of several key areas:

• The excision site and surrounding tissue for signs of local recurrence
• Regional lymph node basins for enlargement or palpable abnormalities
• The skin between the primary site and regional lymph nodes for in-transit metastases, particularly in melanoma patients
• The entire skin surface for new primary skin cancers or suspicious lesions

Dermoscopy is routinely employed during surveillance visits to enhance the clinical examination. In certain cases, imaging studies may be ordered to evaluate for distant metastatic disease, particularly in patients with higher-stage melanoma.

Recurrence Detection

Local recurrence typically presents as a new or growing lesion at or near the original treatment site. For basal cell carcinoma and squamous cell carcinoma, recurrence most commonly occurs within the first 2 to 3 years following treatment. Melanoma recurrence may occur much later, with some cases presenting more than 10 years after initial treatment.

When recurrence is suspected, a biopsy is performed to confirm the diagnosis. The treatment approach for recurrent disease depends on the location, extent, and type of recurrence, and may involve surgical excision, Mohs micrographic surgery, or referral for additional therapies.

Long-term Follow-Up

Even after the initial intensive surveillance period has concluded, long-term annual skin examinations remain important. The risk of developing a new primary skin cancer persists indefinitely, and ongoing monitoring ensures that any new lesions are identified and treated early. Patients are also encouraged to perform regular self-examinations and to report any new or changing lesions between scheduled visits.

At the Centre for Medical and Surgical Dermatology, Dr. Maksym Breslavets provides comprehensive post-treatment surveillance for patients who have been treated for skin cancer. Individualized surveillance schedules are established based on the specific cancer type, stage, and risk factors, with clinical examination and dermoscopy used to monitor for recurrence and new primary tumours.